Moors & Cabot’s Johnson & Johnson JNJ Stock Holding History

Moors & Cabot’s Portfolio JNJ Stock Details JNJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,000	Closed	-$17K	–	533
2016 Q1	$17K	Hold	1,000	–	–	﹤0.01%	508
2015 Q4	$13K	Hold	1,000	–	–	﹤0.01%	503
2015 Q3	$1K	Hold	1,000	–	–	﹤0.01%	505
2015 Q2	$3K	Hold	1,000	–	–	﹤0.01%	524
2015 Q1	$5K	Buy	+1,000	New	+$102K	﹤0.01%	512

Other funds holding JNJ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Moors & Cabot's JNJ Position: Q2 2026 in Review

Moors & Cabot increased its Johnson & Johnson (JNJ) stake by 0.3% in Q2 2026, buying an estimated $83K and bringing the position to 120,434 shares worth $30.6M. The position accounts for 1.19% of the portfolio, ranked #9.

Moors & Cabot first reported a position in JNJ in Q1 2014 and has held it in 50 quarters since. 4,689 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

Moors & Cabot held 120,434 shares of Johnson & Johnson worth $30.6M as of Q2 2026.
Moors & Cabot bought 356 Johnson & Johnson shares in Q2 2026, an estimated $83K.
Johnson & Johnson made up 1.19% of Moors & Cabot's portfolio in Q2 2026, its #9 holding.
Moors & Cabot first reported a position in Johnson & Johnson in Q1 2014 and has held it in 50 quarters since.
4,689 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.